Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Oct;76(4):1657–1664. doi: 10.1172/JCI112151

Selective expression of phosphoribosylpyrophosphate synthetase superactivity in human lymphoblast lines.

M J Losman, D Rimon, M Kim, M A Becker
PMCID: PMC424156  PMID: 2414323

Abstract

Phenotypic expression of 5-phosphoribosyl 1-pyrophosphate (PRPP) synthetase superactivity was examined in lymphoblast lines derived from six unrelated male patients. Fibroblasts from these individuals have increased rates of PRPP and purine nucleotide synthesis and express four classes of kinetic derangement underlying enzyme superactivity: increased maximal reaction velocity (catalytic defect); inhibitor resistance (regulatory defect); increased substrate affinity (substrate binding defect); and combined catalytic and regulatory defects. Lymphoblast lines from three patients with catalytic defects and from three normal individuals were indistinguishable with respect to enzyme activities, PRPP concentrations and generation, and rates of purine synthesis. Enzyme in lymphoblasts from a patient with combined defects also showed normal maximal reaction velocity but expressed purine nucleotide inhibitor resistance. A second regulatory defect and a substrate binding defect were also demonstrable in lymphoblasts and were identical to the enzyme defects in fibroblasts from the respective patients. Regulatory and substrate binding defects in lymphoblasts were accompanied by increased rates of PRPP and purine nucleotide synthesis. Among explanations for selective expression of enzyme superactivity, reduced concentrations of catalytically superactive enzymes seemed unlikely: immunoreactive PRPP synthetase was comparable in normal-derived and patient-derived cells. Activation of normal enzyme in transformed lymphocytes was also unlikely because absolute specific activities of lymphoblast PRPP synthetases corresponded to those of normal fibroblast and erythrocyte enzymes. Abnormal electrophoretic mobilities and thermal stabilities, identified in certain catalytically superactive fibroblast PRPP synthetases, were not found in the corresponding lymphoblast enzymes. Thus, lymphoblast PRPP synthetases from patients with catalytic superactivity appeared to differ structurally and functionally from their fibroblast counterparts.

Full text

PDF
1657

Images in this article

1660Image
on p.1660
1661Image
on p.1661

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akaoka I., Fujimori S., Kamatani N., Takeuchi F., Yano E., Nishida Y., Hashimoto A., Horiuchi Y. A gouty family with increased phosphoribosylpyrophosphate synthetase activity: case reports, familial studies, and kinetic studies of the abnormal enzyme. J Rheumatol. 1981 Jul-Aug;8(4):563–574. [PubMed] [Google Scholar]
  2. Becker M. A., Kostel P. J., Meyer L. J. Human phosphoribosylpyrophosphate synthetase. Comparison of purified normal and mutant enzymes. J Biol Chem. 1975 Sep 10;250(17):6822–6830. [PubMed] [Google Scholar]
  3. Becker M. A., Losman M. J., Itkin P., Simkin P. A. Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate. J Lab Clin Med. 1982 Apr;99(4):495–511. [PubMed] [Google Scholar]
  4. Becker M. A., Meyer L. J., Huisman W. H., Lazar C., Adams W. B. Human erythrocyte phosphoribosylpyrophosphate synthetase. Subunit analysis and states of subunit association. J Biol Chem. 1977 Jun 10;252(11):3911–3918. [PubMed] [Google Scholar]
  5. Becker M. A., Meyer L. J., Seegmiller J. E. Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity. Am J Med. 1973 Aug;55(2):232–242. doi: 10.1016/0002-9343(73)90174-5. [DOI] [PubMed] [Google Scholar]
  6. Becker M. A., Meyer L. J., Wood A. W., Seegmiller J. E. Purine overproduction in man associated with increased phosphoribosylpyrophosphate synthetase activity. Science. 1973 Mar 16;179(4078):1123–1126. doi: 10.1126/science.179.4078.1123. [DOI] [PubMed] [Google Scholar]
  7. Becker M. A. Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction. J Clin Invest. 1976 Feb;57(2):308–318. doi: 10.1172/JCI108282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Becker M. A., Raivio K. O., Bakay B., Adams W. B., Nyhan W. L. Variant human phosphoribosylpyrophosphate synthetase altered in regulatory and catalytic functions. J Clin Invest. 1980 Jan;65(1):109–120. doi: 10.1172/JCI109640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Becker M. A., Raivio K. O., Seegmiller J. E. Synthesis of phosphoribosylpyrophosphate in mammalian cells. Adv Enzymol Relat Areas Mol Biol. 1979;49:281–306. doi: 10.1002/9780470122945.ch7. [DOI] [PubMed] [Google Scholar]
  10. Becker M. A., Seegmiller J. E. Recent advances in the identification of enzyme abnormalities underlying excessive purine synthesis in man. Arthritis Rheum. 1975 Nov-Dec;18(6 Suppl):687–694. doi: 10.1002/art.1780180708. [DOI] [PubMed] [Google Scholar]
  11. Becker M. A., Yen R. C., Itkin P., Goss S. J., Seegmiller J. E., Bakay B. Regional localization of the gene for human phosphoribosylpyrophosphate synthetase on the X chromosome. Science. 1979 Mar 9;203(4384):1016–1019. doi: 10.1126/science.218284. [DOI] [PubMed] [Google Scholar]
  12. Boss G. R. Decreased phosphoribosylpyrophosphate as the basis for decreased purine synthesis during amino acid starvation of human lymphoblasts. J Biol Chem. 1984 Mar 10;259(5):2936–2941. [PubMed] [Google Scholar]
  13. Boyle J. A., Raivio K. O., Becker M. A., Seegmiller J. E. Effects of nicotinic acid on human fibroblast purine biosynthesis. Biochim Biophys Acta. 1972 May 10;269(2):179–183. doi: 10.1016/0005-2787(72)90424-8. [DOI] [PubMed] [Google Scholar]
  14. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  15. Chambers D. A., Martin D. W., Jr, Weinstein Y. The effect of cyclic nucleotides on purine biosynthesis and the induction of PRPP synthetase during lymphocyte activation. Cell. 1974 Dec;3(4):375–380. doi: 10.1016/0092-8674(74)90053-1. [DOI] [PubMed] [Google Scholar]
  16. Choi K. W., Bloom A. D. Biochemically marked lymphocytoid lines: establishment of Lesch-Nyhan cells. Science. 1970 Oct 2;170(3953):89–90. doi: 10.1126/science.170.3953.89. [DOI] [PubMed] [Google Scholar]
  17. Crabtree G. W., Henderson J. F. Rate-limiting steps in the interconversion of purine ribonucleotides in Ehrlich ascites tumor cells in vitro. Cancer Res. 1971 Jul;31(7):985–991. [PubMed] [Google Scholar]
  18. Fox I. H., Kelley W. N. Human phosphoribosylpyrophosphate synthetase. Kinetic mechanism and end product inhibition. J Biol Chem. 1972 Apr 10;247(7):2126–2131. [PubMed] [Google Scholar]
  19. Glade P. R., Beratis N. G. Long-term lymphoid cell lines in the study of human genetics. Prog Med Genet. 1976;1:1–48. [PubMed] [Google Scholar]
  20. Green C. D., Martin D. W., Jr A direct, stimulating effect of cyclic GMP on purified phosphoribosyl pyrophosphate synthetase and its antagonism by cyclic AMP. Cell. 1974 Aug;2(4):241–245. doi: 10.1016/0092-8674(74)90017-8. [DOI] [PubMed] [Google Scholar]
  21. HENDERSON J. F. Feedback inhibition of purine biosynthesis in ascites tumor cells. J Biol Chem. 1962 Aug;237:2631–2635. [PubMed] [Google Scholar]
  22. Hershfield M. S., Seegmiller J. E. Regulation of de novo purine biosynthesis in human lymphoblasts. Coordinate control of proximal (rate-determining) steps and the inosinic acid branch point. J Biol Chem. 1976 Dec 10;251(23):7348–7354. [PubMed] [Google Scholar]
  23. Hershfield M. S., Seegmiller J. E. Regulation of de novo purine synthesis in human lymphoblasts. Similar rates of de novo synthesis during growth by normal cells and mutants deficient in hypoxanthine-guanine phosphoribosyltransferase activity. J Biol Chem. 1977 Sep 10;252(17):6002–6010. [PubMed] [Google Scholar]
  24. Hershko A., Razin A., Mager J. Regulation of the synthesis of 5-phosphoribosyl-I-pyrophosphate in intact red blood cells and in cell-free preparations. Biochim Biophys Acta. 1969 Jun 17;184(1):64–76. doi: 10.1016/0304-4165(69)90099-3. [DOI] [PubMed] [Google Scholar]
  25. Huisman W. H., Raivio K. O., Becker M. A. Simultaneous estimation of rates of pyrimidine and purine nucleotide synthesis de novo in cultured human cells. J Biol Chem. 1979 Dec 25;254(24):12595–12602. [PubMed] [Google Scholar]
  26. Itkin P., Woo S., Becker M. A. Human phosphoribosylpyrophosphate synthetase: radioimmunochemical quantitation in erythrocytes and fibroblasts. J Lab Clin Med. 1984 Jul;104(1):96–109. [PubMed] [Google Scholar]
  27. Johnson M. G., Rosenweig S., Switzer R. L., Becker M. A., Seegmiller J. E. Evaluation of the role of 5-phosphoribosyl-alpha-1-pyrophosphate synthetase in congenital hyperuricemia and gout: a simple isotopic assay and an activity stain for the enzyme. Biochem Med. 1974 Jul;10(3):266–275. doi: 10.1016/0006-2944(74)90030-1. [DOI] [PubMed] [Google Scholar]
  28. KORNBERG A., LIEBERMAN I., SIMMS E. S. Enzymatic synthesis and properties of 5-phosphoribosylpyrophosphate. J Biol Chem. 1955 Jul;215(1):389–402. [PubMed] [Google Scholar]
  29. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  30. Lejeune E., Bouvier M., Mousson B., Llorca G., Baltassat P. Anomalies de la phosphoribosylpyrophosphate synthétase dans deux cas de goutte à début précoce. Rev Rhum Mal Osteoartic. 1979 Jul-Sep;46(7-9):457–465. [PubMed] [Google Scholar]
  31. Lever J. E., Nuki G., Seegmiller J. E. Expression of purine overproduction in a series of 8-azaguanine-resistant diploid human lymphoblast lines. Proc Natl Acad Sci U S A. 1974 Jul;71(7):2679–2683. doi: 10.1073/pnas.71.7.2679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Levy J. A., Virolainen M., Defendi V. Human lymphoblastoid lines from lymph node and spleen. Cancer. 1968 Sep;22(3):517–524. doi: 10.1002/1097-0142(196809)22:3<517::aid-cncr2820220305>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  33. Losman M. J., Hecker S., Woo S., Becker M. A. Diagnostic evaluation of phosphoribosylpyrophosphate synthetase activities in hemolysates. J Lab Clin Med. 1984 Jun;103(6):932–943. [PubMed] [Google Scholar]
  34. Martin D. W., Jr, Owen N. T. Repression and derepression of purine biosynthesis in mammalian hepatoma cells in culture. J Biol Chem. 1972 Sep 10;247(17):5477–5485. [PubMed] [Google Scholar]
  35. Mittal K. K., Mickey M. R., Singal D. P., Terasaki P. I. Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test. Transplantation. 1968 Nov;6(8):913–927. doi: 10.1097/00007890-196811000-00006. [DOI] [PubMed] [Google Scholar]
  36. Müller M. M., Frank O. Lipid and purine metabolism in benign symmetric lipomatosis. Adv Exp Med Biol. 1974;41:509–516. doi: 10.1007/978-1-4757-1433-3_18. [DOI] [PubMed] [Google Scholar]
  37. Nyhan W. L., James J. A., Teberg A. J., Sweetman L., Nelson L. G. A new disorder of purine metabolism with behavioral manifestations. J Pediatr. 1969 Jan;74(1):20–27. doi: 10.1016/s0022-3476(69)80004-1. [DOI] [PubMed] [Google Scholar]
  38. Pilz R. B., Willis R. C., Boss G. R. The influence of ribose 5-phosphate availability on purine synthesis of cultured human lymphoblasts and mitogen-stimulated lymphocytes. J Biol Chem. 1984 Mar 10;259(5):2927–2935. [PubMed] [Google Scholar]
  39. Raivio K. O., Seegmiller E. Adenine, hypoxanthine and guanine metabolism in fibroblasts from normal individuals and from patients with hypoxanthine phosphoribosyltransferase deficiency. Biochim Biophys Acta. 1973 Mar 19;299(2):273–282. doi: 10.1016/0005-2787(73)90350-x. [DOI] [PubMed] [Google Scholar]
  40. Rosenbloom F. M., Henderson J. F., Caldwell I. C., Kelley W. N., Seegmiller J. E. Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem. 1968 Mar 25;243(6):1166–1173. [PubMed] [Google Scholar]
  41. Simmonds H. A., Webster D. R., Wilson J., Lingham S. An X-linked syndrome characterised by hyperuricaemia, deafness, and neurodevelopmental abnormalities. Lancet. 1982 Jul 10;2(8289):68–70. doi: 10.1016/s0140-6736(82)91690-7. [DOI] [PubMed] [Google Scholar]
  42. Sperling O., Boer P., Persky-Brosh S., Kanarek E., De Vries A. Altered kinetic property of erythrocyte phosphoribosylpsyrophosphate synthetase in excessive purine production. Rev Eur Etud Clin Biol. 1972 Aug-Sep;17(7):703–706. [PubMed] [Google Scholar]
  43. Sperling O., Persky-Brosh S., Boer P., De Vries A. Human erythrocyte phosphoribosylpyrophosphate synthetase mutationally altered in regulatory properties. Biochem Med. 1973 Jun;7(3):389–395. doi: 10.1016/0006-2944(73)90059-8. [DOI] [PubMed] [Google Scholar]
  44. Ullman B., Wormsted M. A., Cohen M. B., Martin D. W., Jr Purine oversecretion in cultured murine lymphoma cells deficient in adenylosuccinate synthetase: genetic model for inherited hyperuricemia and gout. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5127–5131. doi: 10.1073/pnas.79.17.5127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Weiner M. S., Bianco C., Nussenzweig V. Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes. Blood. 1973 Dec;42(6):939–946. [PubMed] [Google Scholar]
  46. Willis R. C., Seegmiller J. E. Increases in purine excretion and rate of synthesis by drugs inhibiting IMP dehydrogenase or adenylosuccinate synthetase activities. Adv Exp Med Biol. 1979;122B:237–241. doi: 10.1007/978-1-4684-8559-2_39. [DOI] [PubMed] [Google Scholar]
  47. Wilson J. M., Baugher B. W., Mattes P. M., Daddona P. E., Kelley W. N. Human hypoxanthine-guanine phosphoribosyltransferase. Demonstration of structural variants in lymphoblastoid cells derived from patients with a deficiency of the enzyme. J Clin Invest. 1982 Mar;69(3):706–715. doi: 10.1172/JCI110499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Wood A. W., Becker M. A., Seegmiller J. E. Purine nucleotide synthesis in lymphoblasts cultured from normal subjects and a patient with Lesch-Nyhan syndrome. Biochem Genet. 1973 Jul;9(3):261–274. doi: 10.1007/BF00485739. [DOI] [PubMed] [Google Scholar]
  49. Wood A. W., Seegmiller J. E. Properties of 5-phosphoribosyl-1-pyrophosphate amidotransferase from human lymphoblasts. J Biol Chem. 1973 Jan 10;248(1):138–143. [PubMed] [Google Scholar]
  50. Yen R. C., Adams W. B., Lazar C., Becker M. A. Evidence for X-linkage of human phosphoribosylpyrophosphate synthetase. Proc Natl Acad Sci U S A. 1978 Jan;75(1):482–485. doi: 10.1073/pnas.75.1.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Yen R. C., Raivio K. O., Becker M. A. Inhibition of phosphoribosylpyrophosphate synthesis in human fibroblasts by 6-methylthioinosinate. J Biol Chem. 1981 Feb 25;256(4):1839–1845. [PubMed] [Google Scholar]
  52. Zoref E., De Vries A., Sperling O. Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts. J Clin Invest. 1975 Nov;56(5):1093–1099. doi: 10.1172/JCI108183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Zoref E., de Vries A., Sperling O. X-linked pattern of inheritance of gout due to mutant feedback-resistant phosphoribosylpyrophosphate synthetase. Adv Exp Med Biol. 1977;76A:287–292. doi: 10.1007/978-1-4613-4223-6_35. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES